ArticleNature cancer2024
Repeated peripheral infusions of anti-EGFRvIII CAR T cells in combination with pembrolizumab show no efficacy in glioblastoma: a phase 1 trial.
Registry-linked trialAbstract readClinical Trial, Phase I
In one paragraph
Article in Nature cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03726515 (Phase 1 Study of EGFRvIII-Directed CAR T Cells Combined With PD-1 Inhibition in Patients With Newly Diagnosed, MGMT-Unmethylated Glioblastoma), which is not on this map. Cited by 133 papers, 6 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
133citing papers in PubMed, 6 pooled it
42.4field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Phase 1 Study of EGFRvIII-Directed CAR T Cells Combined With PD-1 Inhibition in Patients With Newly Diagnosed, MGMT-Unmethylated Glioblastoma
Who cites it
133 citing papers in PubMed, 6 syntheses or guidelines pooled it, 150 citations in OpenAlex.
- Efficacy of CAR-T-Cell-Based Immunotherapies in Patients With Glioma: A Systematic Review and Meta-Analysis.Journal of cellular and molecular medicine · 2026Pooled it
- Locoregional delivery of CAR T cells in high-grade gliomas: a systematic analysis of safety, efficacy, and emerging biomarkers of response.Journal for immunotherapy of cancer · 2026Pooled it
- Receptor tyrosine kinase targeted therapies in glioblastoma: a systematic review.Frontiers in medicine · 2026Pooled it
- Prevalence of human cytomegalovirus in glioblastoma multiforme: a systematic review and meta-analysis.Journal of neuro-oncology · 2025Pooled it
- Single-cell meta-analysis of T cells reveals clonal dynamics of response to checkpoint immunotherapy.Cell genomics · 2025Pooled it
- The Prognostic Significance of Epidermal Growth Factor Receptor Amplification and Epidermal Growth Factor Receptor Variant III Mutation in Glioblastoma: A Systematic Review and Meta-Analysis with Implications for Targeted Therapy.International journal of molecular sciences · 2025Pooled it
- Glioblastoma immune landscape remodeling following treatment with CD70-targeted CAR-T cells.Oncoimmunology · 2026Article
- Oncolytic virus OVV-03 enhances CAR-T cell therapy against glioblastoma via immune modulation and specific HER2 upregulation.Oncoimmunology · 2026Article
- Brain barriers at the crossroads of glioma immune surveillance and immunotherapy response.Nature reviews. Cancer · 2026Review
- CRISPR in clinical oncology: translational advances from molecular diagnostics to therapeutics.Nature reviews. Clinical oncology · 2026Review
- Recent Locoregional CAR T-Cell Trials for the Treatment of Recurrent Glioblastoma: Implications for Neuro-Oncology Practice.CNS drugs · 2026Review
- Immunotherapy for Newly Diagnosed Glioblastoma: Current Evidence and Future Perspectives.Journal of personalized medicine · 2026Review
- Generation of Allogeneic CAR-T Circumvents Functional Deficits in Patient-Derived Autologous Product for Glioblastoma.International journal of cancer · 2026Article
- scXpand: Pan-cancer detection of T cell clonal expansion from single-cell RNA sequencing without paired single-cell TCR sequencing.Cell genomics · 2026Article
- Chimeric antigen receptor (CAR)-T cell therapy for solid tumors in pediatric patients: current breakthroughs, dilemmas, and strategies.Experimental hematology & oncology · 2026Review
- CAR-T cell therapy: potential for paediatric brain tumours-an update.Journal of neuro-oncology · 2026Review
- The critical role of the endogenous immune compartment after CAR T cell therapy in recurrent GBM.Cell · 2026Article
- Mechanisms of Therapeutic Resistance and Recent Advances in Glioblastoma Treatment.Immunology and cell biology · 2026Review
- CD47 monoclonal antibody enhances the inhibitory effect of anti-HER2 chimeric antigen receptor macrophages on ovarian cancer.Oncology letters · 2026Article
- Nanomaterials Drive In Vivo CAR Immune Cells Engineering.Advanced materials (Deerfield Beach, Fla.) · 2026Review
73 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
35 authors at 9 institutions in 4 countries.
Stephen J Bagley *Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA. sbagley@pennmedicine.upenn.edu.ORCID http://orcid.org/0000-0002-7117-0539
Zev A Binder *Department of Neurosurgery, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.ORCID http://orcid.org/0000-0003-1158-231X
Lamia Lamrani *Clinical Immunology Laboratory, Institut Curie, Paris, France.
Eliana MarinariAgora Cancer Research Center, Lausanne, Switzerland.
Arati S DesaiDepartment of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
MacLean P NasrallahGBM Translational Center of Excellence, Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.ORCID http://orcid.org/0000-0003-4861-0898
Eileen MaloneyDepartment of Neurosurgery, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
Steven BremDepartment of Neurosurgery, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.ORCID http://orcid.org/0000-0002-5803-8920
Robert A LustigDepartment of Radiation Oncology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
Goldie KurtzDepartment of Radiation Oncology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
Michelle Alonso-BasantaDepartment of Radiation Oncology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
Pierre-Emmanuel BontéINSERM U932, PSL University, Immunity and Cancer, Institut Curie Research Center, Paris, France.ORCID http://orcid.org/0000-0002-9732-5826
Christel GoudotINSERM U932, PSL University, Immunity and Cancer, Institut Curie Research Center, Paris, France.
Wilfrid RicherINSERM U932, PSL University, Immunity and Cancer, Institut Curie Research Center, Paris, France.
Eliane PiaggioINSERM U932, PSL University, Immunity and Cancer, Institut Curie Research Center, Paris, France.
Shawn KothariDepartment of Hematology and Medical Oncology, Emory University, Atlanta, GA, USA.
Lea GuyonnetCytometry Platform, CurieCoreTech, Institut Curie, Paris, France.
Coralie L GuerinCytometry Platform, CurieCoreTech, Institut Curie, Paris, France.ORCID http://orcid.org/0000-0002-1840-4017
Joshua J WaterfallDepartment of Translational Research, PSL Research University, Institut Curie Research Center, Paris, France.ORCID http://orcid.org/0000-0002-3762-5050
Suyash MohanDepartment of Radiology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.ORCID http://orcid.org/0000-0002-4025-115X
Wei-Ting HwangDepartment of Biostatistics, Epidemiology, and Informatics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.ORCID http://orcid.org/0000-0003-2829-2167
Oliver Y TangGBM Translational Center of Excellence, Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
Meghan LogunDepartment of Neurosurgery, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
Meghna BhattacharyyaGBM Translational Center of Excellence, Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
Kelly MarkowitzDepartment of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
Devora DelmanDepartment of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
Amy MarshallCenter for Cellular Immunotherapies, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
E John WherryParker Institute for Cancer Immunotherapy, San Francisco, CA, USA.ORCID http://orcid.org/0000-0003-0477-1956
Sebastian AmigorenaINSERM U932, PSL University, Immunity and Cancer, Institut Curie Research Center, Paris, France.ORCID http://orcid.org/0000-0001-8583-8416
Gregory L BeattyDepartment of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
Jennifer L BrogdonNovartis Institutes for BioMedical Research, Cambridge, MA, USA.
Elizabeth HexnerDepartment of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
Denis MiglioriniAgora Cancer Research Center, Lausanne, Switzerland.ORCID http://orcid.org/0000-0003-0151-3222
Cecile AlanioClinical Immunology Laboratory, Institut Curie, Paris, France. cecile.alanio@curie.fr.ORCID http://orcid.org/0000-0003-2785-7445
Donald M O'RourkeDepartment of Neurosurgery, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
University of Pennsylvania · USInserm · FRInstitut Curie · FRUniversity of Geneva · CHBrown University · USCooper Medical School of Rowan University · USEmory University · USNovartis (United States) · USParker Institute for Cancer Immunotherapy · US
Funding
Agence Nationale de la Recherche (French National Research Agency) ANR-10-EQPX-03Agence Nationale de la Recherche (French National Research Agency) ANR-10-INBS-09-08Agence Nationale de la Recherche (French National Research Agency) ANR-21-RHUS-0016
Abstract
We previously showed that chimeric antigen receptor (CAR) T-cell therapy targeting epidermal growth factor receptor variant III (EGFRvIII) produces upregulation of programmed death-ligand 1 (PD-L1) in the tumor microenvironment (TME). Here we conducted a phase 1 trial (NCT03726515) of CAR T-EGFRvIII cells administered concomitantly with the anti-PD1 (aPD1) monoclonal antibody pembrolizumab in patients with newly diagnosed, EGFRvIII
Indexed as
Antibodies, Monoclonal, HumanizedGlioblastomaErbB ReceptorsHumansNeoplasm Recurrence, LocalT-LymphocytesTumor MicroenvironmentAntibodies, Monoclonal, HumanizedErbB Receptorspembrolizumab
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
NCT03726515ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.